Living with pleural mesothelioma, a rare and aggressive cancer of the chest lining, presents a difficult road for many patients. When doctors perform cytoreductive surgery to remove the tumor, they are looking for ways to improve long-term outcomes. New data suggests that adding heat to the chemotherapy process during these surgeries could help.
A large review of 1,060 patients found that those who received hyperthermic intrathoracic chemotherapy (HITHOC) lived longer than those who did not. Specifically, the median survival for the HITHOC group was about 21 months, compared to roughly 19 months for the standard surgery group. This suggests a meaningful difference in how long patients can live after their procedure.
Importantly, this extra step of heating the chemotherapy did not seem to increase immediate risks. The study found no significant differences in early complications like heart rhythm issues or infections. While this analysis shows a clear link between heat treatment and longer survival, it is based on existing data rather than a single new trial. Talk with your doctor about how these findings might apply to specific treatment plans.
